Atopic Dermatitis (Eczema).Care & specialists in United Kingdom

Eczema is not curable in the strict sense, but it is highly controllable. Most children outgrow the worst of their disease by adolescence (roughly 50-60% are in clinical remission by age 18), and adults with persistent disease can achieve clear or almost-clear skin on modern therapy. Daily moisturizing, trigger avoidance, topical anti-inflammatories, and (when needed) biologics such as dupilumab keep flares to a minimum and protect quality of life over the long term.

Eczema is driven by a defective skin barrier (often involving filaggrin gene variants and ceramide deficiency) combined with an overactive type 2 immune response that releases interleukin-4, interleukin-13, and interleukin-31. Genetics set susceptibility; environmental triggers such as soaps, dust mite, dry air, stress, and Staphylococcus aureus colonization tip a stable barrier into an active flare.

Eczema produces dry, itchy, red, scaly patches that may weep clear fluid during flares and become thickened (lichenified) over time. In infants it affects cheeks, scalp, and outer arms and legs; in older children and adults it favours the inner elbows, behind the knees, neck, wrists, and ankles. The skin between flares is typically dry, rough, and sensitive.

Eczema is diagnosed clinically by a dermatologist or primary-care clinician using the Hanifin-Rajka or UK Working Party criteria — an itchy condition plus features such as flexural involvement, atopic history, early onset, and chronic dry skin. No blood test confirms it. Patch testing is used when allergic contact dermatitis is suspected, and biopsy is reserved for atypical or treatment-resistant adult cases.

The best moisturizers are thick, fragrance-free, and contain ceramides, cholesterol, and free fatty acids that replicate the natural skin barrier. Ointments and creams outperform lotions. Apply within three minutes of bathing and at least twice a day, even on skin that looks clear. Brands carrying the National Eczema Association Seal of Acceptance meet most evidence criteria.

Yes, topical corticosteroids are safe and effective when used correctly. Match potency to the site (low on face and folds, mid on body, high for thick plaques), use the fingertip-unit dosing method, and apply once or twice daily during flares. Long-term twice-weekly proactive use is also safe and halves relapse rates. Atrophy, stretch marks, and rosacea-like reactions occur only with prolonged misuse, particularly of high-potency steroids on the face.

Dupilumab is a monoclonal antibody that blocks the interleukin-4 receptor alpha chain, shutting down IL-4 and IL-13 signalling. It is the first-line systemic therapy for moderate-to-severe eczema in patients aged 6 months and older whose disease fails optimized topical therapy. It is given as a subcutaneous injection every 2 weeks. About half of treated patients achieve a 75% improvement in EASI scores within 16 weeks.

Most do. About half to 60% of children with infant-onset eczema have substantially improved or clear skin by adolescence. Predictors of persistence include severe early disease, multiple food and environmental sensitizations, and filaggrin gene variants. Early consistent treatment may also reduce the risk of progressing to asthma and hay fever.

No, eczema itself is not contagious. You cannot catch it from skin contact or sharing towels. Secondary infections that complicate eczema — bacterial impetigo, herpes simplex (eczema herpeticum), molluscum contagiosum — can spread to others, so cover oozing or vesicular areas and seek treatment for sudden worsening.

For most patients, food is not the main driver. About 30% of infants with moderate-severe eczema have a true IgE-mediated food allergy (commonly to milk, egg, peanut, wheat, or soy), which can flare the skin within minutes to hours of exposure. Broad elimination diets without confirmed allergy worsen growth and can cause loss of food tolerance — avoid them unless directed by an allergist.

Treat the inflammation first — a topical corticosteroid or calcineurin inhibitor cuts itch within days. Cool compresses, fragrance-free moisturizer, short cotton gloves at night, and shorter lukewarm showers all help. Non-sedating antihistamines do not relieve atopic itch but sedating ones may aid sleep. For severe itch, dupilumab and oral JAK inhibitors reduce itch within 24-48 hours.

Stress does not cause eczema but is a major flare trigger. Stress releases neuropeptides that lower the itch threshold and disrupt the barrier, while sleep loss amplifies the itch-scratch cycle. Habit-reversal training, cognitive-behavioural therapy, and sleep hygiene reduce flare frequency in chronic disease.

Eczema is intensely itchy, ill-defined, and oozes in flares, favouring flexural creases such as the inner elbows and behind the knees. Psoriasis presents as well-demarcated thick red plaques with silvery scale on extensor surfaces, scalp, and lumbosacral area, with milder itch and often nail or joint involvement. A dermatologist can usually tell them apart on examination, and biopsy resolves rare overlap.

Yes. Adult-onset atopic dermatitis is recognized in 1-3% of adults and often presents on the hands, eyelids, and head and neck. Triggers, contact allergens, and occupational exposures should be carefully reviewed. Treatment ladder is the same as in childhood disease, with biologics and JAK inhibitors widely used.

Dilute-bleach baths can help patients with moderate-severe eczema or frequent skin infections. Add a quarter cup of 6% household bleach to a full bathtub of lukewarm water, soak for 10 minutes, twice weekly, then rinse and moisturize. Randomized trials show roughly a 35% reduction in EASI in children prone to infection. Skip the bleach bath if skin is acutely fissured.

Yes. Both are part of the atopic march, with shared type 2 inflammation. About 30-50% of children with moderate-severe eczema develop asthma, and 40-60% develop allergic rhinitis. Effective eczema control in early childhood may reduce later atopic progression, though this is still under study.

Generic emollients, topical corticosteroids, and calcineurin inhibitors are inexpensive — often under USD 50 a month combined. Biologics such as dupilumab and oral JAK inhibitors run several thousand dollars per month at US list price but are widely covered by insurance for moderate-severe disease meeting guideline criteria. In India and most emerging markets, allopurinol-tier generic topical therapy is widely affordable while biologic access is improving.

Yes. Daily emollients, low-to-mid potency topical corticosteroids on small areas, and narrowband UVB phototherapy are considered safe in pregnancy. Topical calcineurin inhibitors are generally avoided. Dupilumab has reassuring registry data and may be continued in moderate-severe disease after discussion with a dermatologist. Oral JAK inhibitors are avoided in pregnancy.

Seek same-day care if you develop sudden painful clustered vesicles with fever (possible eczema herpeticum), spreading honey-coloured crusting and fever (bacterial superinfection), generalized peeling and chills (erythroderma), or eye pain and vision change. These complications can progress rapidly and need prompt antiviral, antibiotic, or hospital care.

Yes. Cold dry winter air lowers skin humidity and worsens eczema; hot humid weather increases sweat and irritation; sudden temperature changes destabilize the barrier. Maintaining indoor humidity around 40-50%, wearing breathable cotton, and showering lukewarm after sweat exposure all help reduce weather-driven flares.

Yes, and you should. Regular exercise improves quality of life and overall health. Wear moisture-wicking fabrics, shower lukewarm within an hour, and reapply emollient afterwards. Chlorinated pools are tolerated by most patients if you rinse and moisturize immediately. Avoid prolonged hot showers and saunas during active flares.